US20210260211A1 - Antibody Drug Conjugates Having Derivatives of Amatoxin As The Drug - Google Patents

Antibody Drug Conjugates Having Derivatives of Amatoxin As The Drug Download PDF

Info

Publication number
US20210260211A1
US20210260211A1 US17/240,700 US202117240700A US2021260211A1 US 20210260211 A1 US20210260211 A1 US 20210260211A1 US 202117240700 A US202117240700 A US 202117240700A US 2021260211 A1 US2021260211 A1 US 2021260211A1
Authority
US
United States
Prior art keywords
compound
alkyl
adc
nhc
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/240,700
Inventor
Tong Zhu
Hong Zhang
Alisher B. Khasanov
Gang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivasor Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Priority to US17/240,700 priority Critical patent/US20210260211A1/en
Publication of US20210260211A1 publication Critical patent/US20210260211A1/en
Assigned to JMB CAPITAL PARTNERS LENDING, LLC reassignment JMB CAPITAL PARTNERS LENDING, LLC SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCINTILLA PHARMACEUTICALS, INC., SORRENTO THERAPEUTICS, INC.
Assigned to SCILEX HOLDING COMPANY reassignment SCILEX HOLDING COMPANY SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCINTILLA PHARMACEUTICALS, INC., SORRENTO THERAPEUTICS, INC.
Assigned to SORRENTO THERAPEUTICS, INC., SCINTILLA PHARMACEUTICALS, INC. reassignment SORRENTO THERAPEUTICS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: JMB CAPITAL PARTNERS LENDING, LLC
Assigned to SORRENTO THERAPEUTICS, INC., SCINTILLA PHARMACEUTICALS, INC. reassignment SORRENTO THERAPEUTICS, INC. TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Assignors: SCILEX HOLDING COMPANY
Assigned to VIVASOR, INC. reassignment VIVASOR, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SORRENTO THERAPEUTICS, INC.
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present disclosure provides derivatives of amanitin conjugated to a targeting antibody to form an ADC (antibody drug conjugate).
  • the amatoxins are rigid bicyclic peptides having eight amino acid units. These compounds are isolated from a variety of mushroom species (e.g., Amanita phalloides (also known as green death cap mushroom), Galerina marginata, Lepiota brunneo - incamata ) or are prepared synthetically. Different mushroom species contain varying amounts of different Amatoxin family members. A member of this family, alpha-amanitin, is known to be an inhibitor of eukaryotic RNA polymerase II (EC2.7.7.6) and to a lesser degree, RNA polymerase III, thereby inhibiting transcription and protein biosynthesis. Wieland (1983) Int. J. Pept. Protein Res. 22(3):257-276. Alpha-amanitin binds non-covalently to RNA polymerase II and dissociates slowly, making enzyme recovery unlikely. Prolonged inhibition of transcription is thought to induce cellular apoptosis.
  • Amanita phalloides also known as green death
  • amatoxins include:
  • ADCs antibody-drug conjugates
  • Toxins used in antibody-toxin conjugates include radioisotopes, bacterial toxins such as diphtheria toxin, plant toxins such as ricin, fungal toxins such as amatoxins (WO2010/115629, WO2012/041504 or WO2012/119787), and small molecule toxins such as geldanamycin (Mandler et al. (2000) J. Natl. Cancer Inst. 92(19):1573-1581; Mandler et al. (2000) Bioorg. Med. Chem. Lett. 10:1025-1028; Mandler et al. (2002) Bioconjugate Chem. 13:786-791), maytansinoids (EP 1391213; Liu et al. (1996) Proc.
  • ZEVALIN® ibritumomab tiuxetan, Biogen/Idec
  • an antibody-radioisotope conjugate composed of a murine IgG1 kappa monoclonal antibody (directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes) connected with an 111In or 90Y radioisotope via a thiourea linker-chelator.
  • ADCs antibody-drug conjugates
  • cytotoxic or cytostatic agents including drugs that kill or inhibit tumor cells
  • ADCs antibody-drug conjugates
  • This type of delivery mechanism helps to minimize toxicity to normal cells that may occur from systemic administration of unconjugated drug agents.
  • the toxins may cause their cytotoxic and cytostatic effects through a variety of mechanisms including tubulin binding.
  • the present disclosure provides improved amatoxin derivatives used in an ADC (antibody drug conjugate) structure. More specifically, the present disclosure provides an antibody drug conjugate (ADC) having the structure of Formula I
  • L 2 -X is a linker having structure of
  • R 4 is hydrogen, C 1-6 alkyl, —(CH 2 CH 2 O) m —, or the combination thereof, and
  • n is an integer from 1-24;
  • D is a drug moiety active agent derived from amatoxin and selected from the group consisting of alpha-amanitin, beta-amanitin, gamma-amanitin, and epsilon-amanitin having the structure below:
  • n is an integer from 1-10;
  • L 2 is a linker selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, —(CH 2 ) p —, —(CH 2 CH 2 O) m —, —C(O)NH—, —NHC(O)—, PAB (p-aminobenzyl), Val-Cit-PAB, Val-Ala-PAB, Ala-Ala-Asn-PAB, —R 6 OC(O)NR 5 —, —R 8 —S—S—R 7 , and combinations thereof,
  • R 5 is selected from the group consisting of hydrogen, C 1-6 alkyl, —(CH 2 ) p —, —(CH 2 CH 2 O) m —, and combinations thereof;
  • R 6 is selected from the group consisting of an amino acid, peptide consisting of up to 10 aminoacids, C 1-6 alkyl, —(CH 2 ) p —, —(CH 2 CH 2 O) m —, —C(O)NH—, —NHC(O)—, PAB, Val-Cit-PAB, Val-Ala-PAB, Ala-Ala-Asn-PAB, and combinations thereof;
  • R 7 is C 2-6 alkylene, or —(CH 2 CH 2 O) m —;
  • R 8 is selected from the group consisting of an amino acid, peptide consisting of up to 10 aminoacids, C 1-6 alkyl, C 1-6 alkylene, substituted C 1-6 alkylene, —C(O)NH—, —C(O)—NH—CHR 9 —CR 10 R 11 —, —NHC(O)—CHR 9 —CR 10 R 11 —, —(CH 2 CH 2 O) m —, PAB, Val-Cit-PAB, Val-Ala-PAB, Ala-Ala-Asn-PAB, and combinations thereof;
  • R 9 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 alkylene, —(CH 2 CH 2 O) m —, —C(O)NH—, —NHC(O)—, —C(O)NH—(CH 2 )p-SO 3 H, C(O)NH—(CH 2 )p-CO 2 H, —NHC(O)—(CH 2 )p-SO 3 H, —NHC(O)—(CH 2 )p-CO 2 H and combinations thereof;
  • R 10 and R 11 are each independently selected from the group consisting of hydrogen, C 1-6 alkyl, and combinations thereof;
  • n is an integer from 1-24;
  • p is an integer from 1-6.
  • L 2 in the compounds having the structure of Formula I is a linker selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, —(CH 2 ) p —, —(CH 2 CH 2 O) m —, —C(O)NH—, —NHC(O)—, PAB (p-aminobenzyl), -Val-Cit-PAB-, -Val-Ala-PAB-, -Ala-Ala-Asn-PAB-, —R 6 OC(O)NR 5 —, —R 8 —S—S—R 7 , and combinations thereof,
  • R 5 is selected from the group consisting of hydrogen, C 1-6 alkyl, —(CH 2 ) p —, —(CH 2 CH 2 O) m —, and combinations thereof;
  • R 6 is selected from the group consisting of an amino acid, peptide consisting of up to 10 aminoacids, C 1-6 alkyl, —(CH 2 ) p —, —(CH 2 CH 2 O) m —, —C(O)NH—, —NHC(O)—, PAB, -Val-Cit-PAB-, -Val-Ala-PAB-, -Ala-Ala-Asn-PAB-, and combinations thereof;
  • R 7 is C 2-6 alkylene, or —(CH 2 CH 2 O) m —;
  • R 8 is selected from the group consisting of an amino acid, peptide consisting of up to 10 aminoacids, C 1-6 alkyl, C 1-6 alkylene, substituted C 1-6 alkylene, —C(O)NH—, —C(O)—NH—CHR 9 —CR 10 R 11 —, —NHC(O)—CHR 9 —CR 10 R 11 —, —(CH 2 CH 2 O) m —, PAB, -Val-Cit-PAB-, -Val-Ala-PAB-, -Ala-Ala-Asn-PAB-, and combinations thereof;
  • R 9 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 alkylene, —(CH 2 CH 2 O) m —, —C(O)NH—, —NHC(O)—, —C(O)NH—(CH 2 )p-SO 3 H, C(O)NH—(CH 2 )p-CO 2 H, —NHC(O)—(CH 2 )p-SO 3 H, —NHC(O)—(CH 2 )p-CO 2 H and combinations thereof;
  • R 10 and R 11 are each independently selected from the group consisting of hydrogen, C 1-6 alkyl, and combinations thereof;
  • n is an integer from 1-24;
  • p is an integer from 1-6, wherein the remaining values are as described above for Formula I.
  • L 2 in the compounds having the structure of Formula I is a linker selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, —(CH 2 ) p —, —(CH 2 CH 2 O) m —, —C(O)NH—, —NH(4-phenyl)CH 2 O—, -Val-Cit-NH(4-phenyl)CH 2 O—, -Val-Ala-NH(4-phenyl)CH 2 O—, -Ala-Ala-Asn-NH(4-phenyl)CH 2 O—, —R 6 OC(O)NR 5 —, —R 8 —S—S—R 7 —, and combinations thereof,
  • R 5 is selected from the group consisting of hydrogen, C 1-6 alkyl, —(CH 2 ) p —, —(CH 2 CH 2 O) m —, and combinations thereof;
  • R 6 is selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, C 1-6 alkyl, —(CH 2 ) p —, —(CH 2 CH 2 O) m —, —C(O)NH—, —NH(4-phenyl)CH 2 —, -Val-Cit-NH(4-phenyl)CH 2 —, -Val-Ala-NH(4-phenyl)CH 2 —, -Ala-Ala-Asn-NH(4-phenyl)CH 2 —, and combinations thereof;
  • R 7 is C 2-6 alkylene, or —(CH 2 CH 2 O) m —;
  • R 8 is selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, C 1-6 alkyl, C 1-6 alkylene, substituted C 1-6 alkylene, —C(O)—NH—CHR 9 —CR 10 R 11 —, —NHC(O)—CHR 9 —CR 10 R 11 —, —(CH 2 CH 2 O) m —, —PAB—, -Val-Cit-NH(4-phenyl)CH 2 —, -Val-Ala-NH(4-phenyl)CH 2 —, -Ala-Ala-Asn-NH(4-phenyl)CH 2 —, and combinations thereof;
  • R 9 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 alkylene, —(CH 2 CH 2 O) m —, —C(O)NH—, —NHC(O)—, —C(O)NH—(CH 2 )p-SO 3 H, —C(O)NH—(CH 2 )p-CO 2 H, —NHC(O)—(CH 2 )p-SO 3 H, —NHC(O)—(CH 2 )p-CO 2 H and combinations thereof;
  • R 10 and R 11 are each independently selected from the group consisting of hydrogen, C 1-6 alkyl, and combinations thereof;
  • n is an integer from 1-24;
  • p is an integer from 1-6, wherein the remaining values are as described above for Formula I.
  • D has a structure of Formula II:
  • R 1 is NH 2 or OR 2 , wherein R 2 is H, or C 1 -C 10 alkyl, and wherein R 3 is H or OH.
  • the disclosed ADC is selected from the group consisting of:
  • FIG. 1 shows a comparison of in vitro cytotoxicity of ADC A (22) and ADC B on four cell lines, one cell line in each of the four panels of FIG. 1 .
  • FIG. 2 shows in vitro cytotoxity of ADC24 (see Table 2).
  • FIG. 3 shows in vitro cytotoxicity of ADC 22 (see Table 2) on various cell lines.
  • FIG. 4 shows in vitro cytotoxicity of ADC 26 on various cell lines.
  • FIG. 5 shows in vitro cytotoxicity of ADC 27 on various cell lines.
  • FIG. 6 shows in vitro cytotoxicity of ADC 25 on various cell lines.
  • FIG. 7 shows in vitro cytotoxicity of ADC 29 on various cell lines.
  • FIG. 8 shows efficacy of cMet/EGFR-22, cMet-22 and Nimo-22 in H292 xenograft: cMet/EGFR-22 and Nimo-22 significantly inhibited H292 tumor growth compared to PBS control group.
  • FIG. 9 shows a tumor size comparison for compound 29.
  • cMet/EFFR-22 and Nimo-22 significantly reduced tumor size/Weight compared to PBS Control group.
  • Nimo-22 had some complete tumor regression (4 out of 7 mice was tumor free).
  • FIG. 10 shows no significant cMet/EGFR-22, cMet-22, Nimo-22 treatment-related body weight loss was observed.
  • FIG. 11 shows cMet/EGFR-23, cMet-23 and Nimo-23 treated groups showed significantly reduced tumor volume compared to PBS Control group.
  • FIG. 12 shows cMet/EGFR-23, cMet-23 and Nimo-23 treated groups showed significantly reduced tumor weight compared to PBS Control group.
  • FIG. 13 shows that no body weight loss was observed in cMet-23, cMet/EGFR-23, and Nimo-23 treated group.
  • FIG. 14 shows that a single dose of cMet/EGFR-25 at 3 mg/kg or 1 mg/kg had no significant tumor growth inhibition in H1975 xenograft.
  • FIG. 15 shows that a single dose of cMet/EGFR-27 at 3 mg/kg or 1 mg/kg, or a single dose of cMet-27 had no significant tumor growth inhibition in HCC827 xenograft.
  • FIG. 16 shows that no significant body weight loss was observed with a single dose of cMet/EGFR-ADC27 at 3 mg/kg or 1 mg/kg, or a single dose of cMet-ADC27 at 0.3 mg/kg during the study.
  • a hyphen (-) designates the point to which a group is attached to the defined variable.
  • a hyphen on the left side indicates connectivity to the left side structural component of formula (I) and hyphen on the right side indicates connectivity to the right side structural component of formula (I).
  • L 2 is defined as —(CH 2 CH 2 ) m —, it means that the attachment to L 1 is at the —CH 2 carbon and the attachment to X is at the oxygen atom.
  • an activated ester e.g. NHS
  • DCM methylene chloride
  • DMF N,N′ dimethyl formamide
  • EDC Ethyl-3-(3-dimethylaminopropyl)carbodiimide
  • the reaction mixture was stirred at room temperature for 1 h until most of the acid was consumed. The progress of the reaction was monitored by RP-HPLC. The mixture was then diluted with DCM and washed successively with citric acid (aq. 10%) and brine. The organic layer was dried and concentrated to dryness.
  • the crude product was optionally purified by RP-HPLC or silica gel column chromatography.
  • Compound 10 was converted to the corresponding activated ester following a general procedure prior to conjugating to an antibody.
  • a comparative study was carried out to evaluate the efficacy of amanitin antibody conjugate structure A wherein alpha-amaintin was attached to the linker via a cleavable carbamate bond (reported in this disclosure) and amanitin antibody conjugate structure B wherein alpha amanitin was attached through a non-cleavable ether bond (reported in WO2012/041504) in various in vitro cell killing assays ( FIG. 1 four panels for four different cell lines.
  • ADC A completely outperformed ADC B in all 4 Her-2 positive cell lines tested.
  • This example provides the results of EC50 assays (nM) of the designated drug conjugated antibodies measured in vitro in specified cells.
  • the antibody used was an anti-HER2 IgG class of antibody.
  • Seven breast cancer cell lines with various level of Her2 expression as indicated with plus or minus signs in the table below were plated in 96 well plate.
  • the ADCs were serial diluted and added onto cells for treatment for 5 days.
  • cell proliferation was measured by Promega's CellTitreGlo.
  • EC50 (in nM) was determined as the concentration of 50% cell growth inhibition.
  • the selection criteria for a successful compound included high efficacy, such as killing cell lines with high expression of the target receptor, with EC50 less than 3 nM.
  • the successful candidate should have low toxicity and good therapeutic window, as determined by relatively low killing of the control cell line (MDA468) with low expression of the target receptor.
  • Both ADCs 22 ( FIG. 3 ) and 24 ( FIG. 2 ) were selected as successful candidates with high efficacy and good therapeutic window.
  • This example provides the results of EC50 assays (nM) of designated ADCs described herein measured in vitro in specified cells.
  • the antibody used targets a receptor tyrosine kinase on cell surface.
  • the ADCs were serial diluted and added onto cells for treatment for 5 days.
  • cell proliferation was measured by Promega's CellTitreGlo.
  • EC50 (in nM) was shown below and determined as the concentration of 50% cell growth inhibition.
  • the selection criteria for a successful compound includes high efficacy, such as killing cell lines with high expression of the target receptor, with EC50 less than 3 nM.
  • the successful candidate should have low toxicity and good therapeutic window, as determined by relatively low killing of the control cell lines (T-47D) with low expression of the target receptor.
  • ADC 25 FIG. 6
  • ADC 26 FIG. 4
  • ADC 27 FIG. 4
  • FIG. 7 shows good cell killing efficacy in cell lines Hs746T, but did not show efficacy in EBC-1, U87, HCC827, H1993 and T-47.
  • HCC827, H292, H1975 cell lines were obtained from ATCC.
  • the cells were cultured in RPMI 1640 1 ⁇ (Corning 10-041-CV) medium with 10% FBS (Seradigm 1500-500) and penicillin streptomycin (Corning 30-002-CI) at 37° C. in a 5% carbon dioxide humidified environment.
  • Cells were cultured for a period of 2 weeks and passaged 4 times before harvest. The cells were harvested with 0.25% trypsin (Corning 25-050-CI).
  • HCC827 cells Prior to injection, HCC827 cells were mixed in a 1:1 ratio of HBSS (Hank's balanced salt solution; Ward's 470180-784) and matrigel (Corning 354234) mixture, and 7 million cells per 0.2 ml were injected subcutaneously into the upper right flank of each mouse.
  • H292 cells were resuspended in HBSS, and 5 million cells per 0.2 ml were injected subcutaneously into the upper right flank of each mouse.
  • H1975 cells were resuspended in HBSS, and 3 million cells per 0.2 ml were injected subcutaneously into the upper right flank of each mouse.
  • mice Female Nu/Nu mice aged 5-7 weeks (Charles River) were used throughout these studies.
  • mice Upon receipt, mice were housed 5 mice per cage in a room with a controlled environment. Rodent chow and water was provided ad libitum. Mice were acclimated to laboratory conditions for 72 hours before the start of dosing. The animals' health status was monitored during the acclimation period. Each cage was identified by group number and study number, and mice were identified individually by ear tags.
  • Group route Frequency H292 1 7 PBS 200 ⁇ l/i.v. 0 mg/kg, single dose 2 7 cMet/EGFR- 200 ⁇ l/i.v. 3 mg/kg, 22 single dose 3 7 cMet-22 200 ⁇ l/i.v. 3 mg/kg, single dose 4 7 Nimo-22 200 ⁇ l/i.v. 3 mg/kg, single dose HCC827 1 7 PBS 200 ⁇ l/i.v. 0 mg/kg, single dose 2 7 cMet/EGFR- 200 ⁇ l/i.v. 3 mg/kg, 23 single dose 3 7 cMet-23 200 ⁇ l/i.v.
  • Tumor growth was monitored by measurement of tumor width and length using a digital caliper starting day 5-7 after inoculation, and followed twice per week until tumor volume reached ⁇ 100-250 mm 3 .
  • Tumor volume was measured twice weekly throughout the experimental period to determine TGI (tumor growth inhibition %).
  • the body weight of each mouse was measured twice weekly by electric balance. Group average and standard deviation were calculated, and statistical analyses (one-way ANOVA with Dunnett's multiple comparison test; GraphPad Prism 6.0) was carried out. All treatment groups were compared with the PBS group. P ⁇ 0.05 was considered statistically significant.
  • a single dose of cMet/EGFR-25 at 3 mg/kg or 1 mg/kg had no significant tumor growth inhibition in H1975 xenograft ( FIG. 14 ).
  • a single dose of cMet/EGFR-27 at 3 mg/kg or 1 mg/kg, or a single dose of cMet-27 at 0.3 mg/kg had no significant tumor growth inhibition in HCC827 xenograft ( FIG. 15 ). No significant body weight loss was observed during the study ( FIG. 16 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

There is disclosed derivatives of amanitin conjugated to a targeting antibody to form an ADC (antibody drug conjugate).

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional application of U.S. patent application Ser. No. 15/609,858, filed May 31, 2017, which claims priority to U.S. provisional patent application No. 62/343,825, filed May 31, 2016, the contents of each of which are incorporated herein by reference.
    • TECHNICAL FIELD
  • The present disclosure provides derivatives of amanitin conjugated to a targeting antibody to form an ADC (antibody drug conjugate).
    • BACKGROUND
  • The amatoxins are rigid bicyclic peptides having eight amino acid units. These compounds are isolated from a variety of mushroom species (e.g., Amanita phalloides (also known as green death cap mushroom), Galerina marginata, Lepiota brunneo-incamata) or are prepared synthetically. Different mushroom species contain varying amounts of different Amatoxin family members. A member of this family, alpha-amanitin, is known to be an inhibitor of eukaryotic RNA polymerase II (EC2.7.7.6) and to a lesser degree, RNA polymerase III, thereby inhibiting transcription and protein biosynthesis. Wieland (1983) Int. J. Pept. Protein Res. 22(3):257-276. Alpha-amanitin binds non-covalently to RNA polymerase II and dissociates slowly, making enzyme recovery unlikely. Prolonged inhibition of transcription is thought to induce cellular apoptosis.
  • Exemplary amatoxins include
  • Figure US20210260211A1-20210826-C00001
    Figure US20210260211A1-20210826-C00002
  • The use of antibody-drug conjugates (ADCs) for the local delivery of cytotoxic or cytostatic agents, including drugs that kill or inhibit tumor cells, allows targeted delivery of the drug moiety to tumors, and intracellular accumulation therein. Syrigos and Epenetos (1999) Anticancer Res. 19:605-614; Niculescu-Duvaz and Springer (1997) Adv. Drug Delivery Rev. 26:151-172; U.S. Pat. No. 4,975,278; Baldwin et al. (1986) Lancet (Mar. 15, 1986):603-05; Thorpe (1985) “Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review,” in Monoclonal Antibodies '84: Biological and Clinical Applications, A. Pinchera et al. (eds.), pp. 475-506. This type of delivery mechanism helps to minimize toxicity to normal cells that may occur from systemic administration of unconjugated drug agents. The toxins may cause their cytotoxic and cytostatic effects through a variety of mechanisms including tubulin binding, DNA binding, or topoisomerase inhibition. Both polyclonal antibodies and monoclonal antibodies have been reported as useful in these strategies. Rowland et al. (1986) Cancer Immunol. Immunother. 21:183-87. Toxins used in antibody-toxin conjugates include radioisotopes, bacterial toxins such as diphtheria toxin, plant toxins such as ricin, fungal toxins such as amatoxins (WO2010/115629, WO2012/041504 or WO2012/119787), and small molecule toxins such as geldanamycin (Mandler et al. (2000) J. Natl. Cancer Inst. 92(19):1573-1581; Mandler et al. (2000) Bioorg. Med. Chem. Lett. 10:1025-1028; Mandler et al. (2002) Bioconjugate Chem. 13:786-791), maytansinoids (EP 1391213; Liu et al. (1996) Proc. Natl. Acad. Sci. USA 93:8618-8623), calicheamicin (Lode et al. (1998) Cancer Res. 58:2928; Hinman et al. (1993) Cancer Res. 53:3336-3342), daunomycin, doxorubicin, methotrexate, and vindesine (Rowland et al. (1986), supra).
  • Several antibody-drug conjugates have shown promising results against cancer in clinical trials, including ZEVALIN® (ibritumomab tiuxetan, Biogen/Idec), an antibody-radioisotope conjugate composed of a murine IgG1 kappa monoclonal antibody (directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes) connected with an 111In or 90Y radioisotope via a thiourea linker-chelator.
  • The use of antibody-drug conjugates (ADCs) for the local delivery of cytotoxic or cytostatic agents, including drugs that kill or inhibit tumor cells, allows targeted delivery of the drug moiety to tumors, and intracellular accumulation therein. This type of delivery mechanism helps to minimize toxicity to normal cells that may occur from systemic administration of unconjugated drug agents. The toxins may cause their cytotoxic and cytostatic effects through a variety of mechanisms including tubulin binding.
  • As such, there remains a need for potent RNA polymerase inhibitor antibody conjugates with desirable pharmaceutical properties.
    • SUMMARY
  • The present disclosure provides improved amatoxin derivatives used in an ADC (antibody drug conjugate) structure. More specifically, the present disclosure provides an antibody drug conjugate (ADC) having the structure of Formula I

  • Ab
    Figure US20210260211A1-20210826-Parenopenst
    L1-L2-X-D)n   (I)
  • or a pharmaceutically acceptable salt thereof,
    wherein:
      • Ab is a monoclonal antibody;
      • L1-L2 is a linker selected from the group consisting of
  • Figure US20210260211A1-20210826-C00003
  • whereby the wavy line indicates the point of attachment to Ab;
  • L2-X is a linker having structure of
  • Figure US20210260211A1-20210826-C00004
  • wherein R4 is hydrogen, C1-6 alkyl, —(CH2CH2O)m—, or the combination thereof, and
  • m is an integer from 1-24;
  • wherein the wavy line indicates the point of attachment to D
  • D is a drug moiety active agent derived from amatoxin and selected from the group consisting of alpha-amanitin, beta-amanitin, gamma-amanitin, and epsilon-amanitin having the structure below:
  •
    Figure US20210260211A1-20210826-C00005
    Name R1 R3
    alpha-amanitin NH2 OH
    beta-amanitin OH OH
    gamma-amanitin NH2 H
    epsilon-amanitin OH H
  • n is an integer from 1-10;
  • L2 is a linker selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, —(CH2)p—, —(CH2CH2O)m—, —C(O)NH—, —NHC(O)—, PAB (p-aminobenzyl), Val-Cit-PAB, Val-Ala-PAB, Ala-Ala-Asn-PAB, —R6OC(O)NR5—, —R8—S—S—R7, and combinations thereof,
  • wherein R5 is selected from the group consisting of hydrogen, C1-6 alkyl, —(CH2)p—, —(CH2CH2O)m—, and combinations thereof;
  • R6 is selected from the group consisting of an amino acid, peptide consisting of up to 10 aminoacids, C1-6 alkyl, —(CH2)p—, —(CH2CH2O)m—, —C(O)NH—, —NHC(O)—, PAB, Val-Cit-PAB, Val-Ala-PAB, Ala-Ala-Asn-PAB, and combinations thereof;
  • R7 is C2-6 alkylene, or —(CH2CH2O)m—;
  • R8 is selected from the group consisting of an amino acid, peptide consisting of up to 10 aminoacids, C1-6 alkyl, C1-6 alkylene, substituted C1-6 alkylene, —C(O)NH—, —C(O)—NH—CHR9—CR10R11—, —NHC(O)—CHR9—CR10R11—, —(CH2CH2O)m—, PAB, Val-Cit-PAB, Val-Ala-PAB, Ala-Ala-Asn-PAB, and combinations thereof;
  • wherein R9 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 alkylene, —(CH2CH2O)m—, —C(O)NH—, —NHC(O)—, —C(O)NH—(CH2)p-SO3H, C(O)NH—(CH2)p-CO2H, —NHC(O)—(CH2)p-SO3H, —NHC(O)—(CH2)p-CO2H and combinations thereof;
  • R10 and R11 are each independently selected from the group consisting of hydrogen, C1-6 alkyl, and combinations thereof;
  • wherein —R6OC(O)NR5— is connected to L1 through R5 or R6;
  • wherein —R8—S—S—R7— is connected to L1 through R8;
  • m is an integer from 1-24; and
  • p is an integer from 1-6.
  • In another aspect, L2 in the compounds having the structure of Formula I is a linker selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, —(CH2)p—, —(CH2CH2O)m—, —C(O)NH—, —NHC(O)—, PAB (p-aminobenzyl), -Val-Cit-PAB-, -Val-Ala-PAB-, -Ala-Ala-Asn-PAB-, —R6OC(O)NR5—, —R8—S—S—R7, and combinations thereof,
  • wherein R5 is selected from the group consisting of hydrogen, C1-6 alkyl, —(CH2)p—, —(CH2CH2O)m—, and combinations thereof;
  • R6 is selected from the group consisting of an amino acid, peptide consisting of up to 10 aminoacids, C1-6 alkyl, —(CH2)p—, —(CH2CH2O)m—, —C(O)NH—, —NHC(O)—, PAB, -Val-Cit-PAB-, -Val-Ala-PAB-, -Ala-Ala-Asn-PAB-, and combinations thereof;
  • R7 is C2-6 alkylene, or —(CH2CH2O)m—;
  • R8 is selected from the group consisting of an amino acid, peptide consisting of up to 10 aminoacids, C1-6 alkyl, C1-6 alkylene, substituted C1-6 alkylene, —C(O)NH—, —C(O)—NH—CHR9—CR10R11—, —NHC(O)—CHR9—CR10R11—, —(CH2CH2O)m—, PAB, -Val-Cit-PAB-, -Val-Ala-PAB-, -Ala-Ala-Asn-PAB-, and combinations thereof;
  • wherein R9 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 alkylene, —(CH2CH2O)m—, —C(O)NH—, —NHC(O)—, —C(O)NH—(CH2)p-SO3H, C(O)NH—(CH2)p-CO2H, —NHC(O)—(CH2)p-SO3H, —NHC(O)—(CH2)p-CO2H and combinations thereof;
  • R10 and R11 are each independently selected from the group consisting of hydrogen, C1-6 alkyl, and combinations thereof;
  • wherein —R6OC(O)NR5— is connected to L1 through R5 or R6;
  • wherein —R8—S—S—R7— is connected to L1 through R8;
  • m is an integer from 1-24; and
  • p is an integer from 1-6, wherein the remaining values are as described above for Formula I.
  • In yet another aspect, L2 in the compounds having the structure of Formula I is a linker selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, —(CH2)p—, —(CH2CH2O)m—, —C(O)NH—, —NH(4-phenyl)CH2O—, -Val-Cit-NH(4-phenyl)CH2O—, -Val-Ala-NH(4-phenyl)CH2O—, -Ala-Ala-Asn-NH(4-phenyl)CH2O—, —R6OC(O)NR5—, —R8—S—S—R7—, and combinations thereof,
  • wherein R5 is selected from the group consisting of hydrogen, C1-6 alkyl, —(CH2)p—, —(CH2CH2O)m—, and combinations thereof;
  • R6 is selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, C1-6 alkyl, —(CH2)p—, —(CH2CH2O)m—, —C(O)NH—, —NH(4-phenyl)CH2—, -Val-Cit-NH(4-phenyl)CH2—, -Val-Ala-NH(4-phenyl)CH2—, -Ala-Ala-Asn-NH(4-phenyl)CH2—, and combinations thereof;
  • R7 is C2-6 alkylene, or —(CH2CH2O)m—;
  • R8 is selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, C1-6 alkyl, C1-6 alkylene, substituted C1-6 alkylene, —C(O)—NH—CHR9—CR10R11—, —NHC(O)—CHR9—CR10R11—, —(CH2CH2O)m—, —PAB—, -Val-Cit-NH(4-phenyl)CH2—, -Val-Ala-NH(4-phenyl)CH2—, -Ala-Ala-Asn-NH(4-phenyl)CH2—, and combinations thereof;
  • wherein R9 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 alkylene, —(CH2CH2O)m—, —C(O)NH—, —NHC(O)—, —C(O)NH—(CH2)p-SO3H, —C(O)NH—(CH2)p-CO2H, —NHC(O)—(CH2)p-SO3H, —NHC(O)—(CH2)p-CO2H and combinations thereof;
  • R10 and R11 are each independently selected from the group consisting of hydrogen, C1-6 alkyl, and combinations thereof;
  • wherein —R6OC(O)NR5— is connected to L1 through R6;
  • wherein —R8—S—S—R7— is connected to L1 through R8;
  • m is an integer from 1-24; and
  • p is an integer from 1-6, wherein the remaining values are as described above for Formula I.
  • Preferably, D has a structure of Formula II:
  • Figure US20210260211A1-20210826-C00006
  • whereby the wavy line indicates the point of attachment to X;
    wherein R1 is NH2 or OR2, wherein R2 is H, or C1-C10 alkyl, and wherein R3 is H or OH.
  • Preferably, the disclosed ADC is selected from the group consisting of:
  • Figure US20210260211A1-20210826-C00007
    Figure US20210260211A1-20210826-C00008
    Figure US20210260211A1-20210826-C00009
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 shows a comparison of in vitro cytotoxicity of ADC A (22) and ADC B on four cell lines, one cell line in each of the four panels of FIG. 1.
  • FIG. 2 shows in vitro cytotoxity of ADC24 (see Table 2).
  • FIG. 3 shows in vitro cytotoxicity of ADC 22 (see Table 2) on various cell lines.
  • FIG. 4 shows in vitro cytotoxicity of ADC 26 on various cell lines.
  • FIG. 5 shows in vitro cytotoxicity of ADC 27 on various cell lines.
  • FIG. 6 shows in vitro cytotoxicity of ADC 25 on various cell lines.
  • FIG. 7 shows in vitro cytotoxicity of ADC 29 on various cell lines.
  • FIG. 8 shows efficacy of cMet/EGFR-22, cMet-22 and Nimo-22 in H292 xenograft: cMet/EGFR-22 and Nimo-22 significantly inhibited H292 tumor growth compared to PBS control group.
  • FIG. 9 shows a tumor size comparison for compound 29. cMet/EFFR-22 and Nimo-22 significantly reduced tumor size/Weight compared to PBS Control group. Nimo-22 had some complete tumor regression (4 out of 7 mice was tumor free).
  • FIG. 10 shows no significant cMet/EGFR-22, cMet-22, Nimo-22 treatment-related body weight loss was observed.
  • FIG. 11 shows cMet/EGFR-23, cMet-23 and Nimo-23 treated groups showed significantly reduced tumor volume compared to PBS Control group.
  • FIG. 12 shows cMet/EGFR-23, cMet-23 and Nimo-23 treated groups showed significantly reduced tumor weight compared to PBS Control group.
  • FIG. 13 shows that no body weight loss was observed in cMet-23, cMet/EGFR-23, and Nimo-23 treated group.
  • FIG. 14 shows that a single dose of cMet/EGFR-25 at 3 mg/kg or 1 mg/kg had no significant tumor growth inhibition in H1975 xenograft.
  • FIG. 15 shows that a single dose of cMet/EGFR-27 at 3 mg/kg or 1 mg/kg, or a single dose of cMet-27 had no significant tumor growth inhibition in HCC827 xenograft.
  • FIG. 16 shows that no significant body weight loss was observed with a single dose of cMet/EGFR-ADC27 at 3 mg/kg or 1 mg/kg, or a single dose of cMet-ADC27 at 0.3 mg/kg during the study.
    •  DETAILED DESCRIPTION
  • TABLE 1
    Examples of compounds synthesized (“Ab” stands for antibody).
    Compound
    # Structure
     6
    Figure US20210260211A1-20210826-C00010
     8
    Figure US20210260211A1-20210826-C00011
    10
    Figure US20210260211A1-20210826-C00012
    14
    Figure US20210260211A1-20210826-C00013
    17
    Figure US20210260211A1-20210826-C00014
    21
    Figure US20210260211A1-20210826-C00015
    28
    Figure US20210260211A1-20210826-C00016
  • TABLE 2
    Examples of antibody drug conjugates of Formula I
    Compound
    # Structure
    22
    Figure US20210260211A1-20210826-C00017
    23
    Figure US20210260211A1-20210826-C00018
    24
    Figure US20210260211A1-20210826-C00019
    25
    Figure US20210260211A1-20210826-C00020
    26
    Figure US20210260211A1-20210826-C00021
    27
    Figure US20210260211A1-20210826-C00022
    29
    Figure US20210260211A1-20210826-C00023
    • Definitions
  • As used herein, common organic abbreviations are defined as follows:
    • Ac Acetyl
  • aq. Aqueous
    BOC or Boc tert-Butoxycarbonyl
    Bu n-Butyl
    ° C. Temperature in degrees Centigrade
    • Cit Citrulline
  • DCM methylene chloride
    • DEPC Diethylcyanophosphonate
  • DIC diisopropylcarbodiimide
    • DIEA Diisopropylethylamine DMA N,N-Dimethylacetamide DMF N,N-Dimethylformamide DMSO Dimethylsulfoxide
  • EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
    • Et Ethyl
  • EtOAc Ethyl acetate
    • Eq Equivalents Fmoc 9-Fluorenylmethoxycarbonyl g Gram(s)
  • h Hour (hours)
    HATU 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium
    hexafluorophosphate
    • HOBT N-Hydroxybenzotriazole HOSu N-Hydroxysuccinimide
  • HPLC High-performance liquid chromatography
    LC/MS Liquid chromatography-mass spectrometry
    • Me Methyl MeOH Methanol MeCN Acetonitrile mL Milliliter(s)
  • MS mass spectrometry
    PAB p-aminobenzyl
    RP-HPLC reverse phase HPLC
    rt room temperature
    t-Bu tert-Butyl
    • TEA Triethylamine
  • Tert, t tertiary
    TFA Trifluoracetic acid
    • THF Tetrahydrofuran
  • TLC Thin-layer chromatography
    • μL Microliter(s)
  • Where used, a hyphen (-) designates the point to which a group is attached to the defined variable. A hyphen on the left side indicates connectivity to the left side structural component of formula (I) and hyphen on the right side indicates connectivity to the right side structural component of formula (I). For example, unless other specified when L2 is defined as —(CH2CH2)m—, it means that the attachment to L1 is at the —CH2 carbon and the attachment to X is at the oxygen atom.
    • General Synthesis Procedure.
  • Formation of an activated ester (e.g. NHS) from an acid An acid was dissolved in DCM (methylene chloride) and DMF (N,N′ dimethyl formamide) was added to aid dissolution if necessary. N-hydroxysuccinimide (1.5 eq) was added, followed by EDC.HCl (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) (1.5 eq). The reaction mixture was stirred at room temperature for 1 h until most of the acid was consumed. The progress of the reaction was monitored by RP-HPLC. The mixture was then diluted with DCM and washed successively with citric acid (aq. 10%) and brine. The organic layer was dried and concentrated to dryness. The crude product was optionally purified by RP-HPLC or silica gel column chromatography.
    • Example 1 Preparation of Compound 6
  • Figure US20210260211A1-20210826-C00024
    Figure US20210260211A1-20210826-C00025
  • To a solution of alpha-amainitin 1 (46 mg, 50 μmol) in anhydrous dimethylsulfoxide (DMSO) (1 mL) was added bis (4-nitrophenol) carbonate (17 mg, 55 mol), followed by diisopropylethylamine (DIEA, 10 μL). The mixture was stirred at room temperature for 30 minutes. Compound 3 (12 mg) was added, followed by DIEA (10 μL). LC/MS indicated all the compound 2 was consumed after 1 h. All the solvents were removed under reduced the pressure and the residue was treated with trifluoroacetic acid (TFA) in dichloromethane (DCM) (20%, v/v, 2 mL). The reaction mixture was concentrated after 30 min and the residue was purified by reverse phase HPLC to give compound 4 as a white solid in TFA salt form after lyophilization (45 mg, 78%). MS: m/z 1033.4 (M+H+).
  • Compound 4 (45 mg) was dissolved in anhydrous dimethylformamide (DMF, 1 mL) and 9-Fluorenylmethyloxycarbonyl-valyl-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)carbonate (Fmoc-Val-Cit-PAB-PNP, 38 mg) was added, followed by DIEA (20 μL). The mixture was stirred at room temperature for 2 h. LC/MS analysis indicated the completion of reaction. Piperidine (50 μL) was added and after 2 h, the reaction mixture was neutralized by addition of acetic acid (200 μL). The crude mixture was purified directly by reverse phase HPLC to give compound 5 as a white solid in TFA salt form after lyophilization (48 mg, 80%). MS: m/z 1438.7 (M+H+).
  • To a stirred solution of compound 5 (16 mg, 10 μmol) in DMF (1 mL) was added N-c-Maleimidocaproyl oxysuccinimide ester (4 mg), followed by DIEA (4 μL). The mixture was stirred at room temperature for 2 h. The crude reaction mixture was injected to a Prep HPLC column for purification. Compound 6 was obtained a white solid after lyophilization. (12 mg). MS: m/z 1631.8 (M+H+).
    • Example 2 Preparation of Compound 8
  • Figure US20210260211A1-20210826-C00026
  • To a stirred solution of compound 5 (16 mg, 10 μmol) in DMF (1 mL) was added acid 7 (6 mg), followed by diisopropylcarbodiimide (5 μL). The mixture was stirred at room temperature for 2 h. The crude reaction mixture was injected to a Prep HPLC column for purification. Compound 8 was obtained a white solid after lyophilization. (8 mg). MS: m/z 1761.8 (M+H+).
    • Example 3 Preparation of Compound 10
  • Figure US20210260211A1-20210826-C00027
  • To a stirred solution of compound 2 (30 μmol) in DMSO (1 mL) was added amine 9 (40 mg), followed by DIEA (15 μL). The mixture was stirred at room temperature for 16 h. The crude reaction mixture was injected to a Prep HPLC column for purification. Compound 10 was obtained a white solid after lyophilization. (32 mg). MS: m/z 2046.2 (M+H+).
  • Compound 10 was converted to the corresponding activated ester following a general procedure prior to conjugating to an antibody.
    • Example 4 Preparation of Compound 14
  • Figure US20210260211A1-20210826-C00028
    Figure US20210260211A1-20210826-C00029
  • To a stirred solution of compound 2 (50 μmol) in DMSO (1 mL) was added amine 11 (65 mg) in DMF (1 mL), followed by DIEA (20 μL). The mixture was stirred at room temperature for 16 h. Piperidine (100 μL) was added. After 30 mins, the mixture was purified directly by reverse phase HPLC to give compound 12 in TFA salt form as a white solid (54 mg). MS: m/z 1862.1 (M+H+).
  • Compound 12 (20 mg) was dissolved in DMF (1 mL). Anhydride 13 (11 mg) was added, followed by DIEA (5 μL). The reaction mixture was stirred at room temperature for 5 minutes and purified by reverse phase HPLC to give compound 14 as a white solid after lyophilization (19 mg). MS: m/z 2203.9 (M+H+).
    • Example 5 Preparation of Compound 17
  • Figure US20210260211A1-20210826-C00030
    Figure US20210260211A1-20210826-C00031
  • To a stirred solution of compound 2 (50 μmol) in DMSO (1 mL) was added amine 15 (65 mg) in DMF (1 mL), followed by DIEA (20 μL). The mixture was stirred at room temperature for 16 h. Piperidine (100 μL) was added. After 30 mins, the mixture was purified directly by reverse phase HPLC to give compound 16 in TFA salt form as a white solid (49 mg). MS: m/z 1862.3 (M+H+).
  • Compound 16 (20 mg) was dissolved in DMF (1 mL). Anhydride 13 (11 mg) was added, followed by DIEA (5 μL). The reaction mixture was stirred at room temperature for 5 minutes and purified by reverse phase HPLC to give compound 17 as a white solid after lyophilization (20 mg). MS: m/z 2204.1 (M+H+).
    • Example 6 Preparation of Compound 21
  • Figure US20210260211A1-20210826-C00032
  • To a stirred solution of compound 2 (50 μmol) in DMSO (1 mL) was added amine 15 (25 mg) in DMF (1 mL), followed by DIEA (20 μL). The mixture was stirred at room temperature for 5 h. The solvents were removed under reduced pressure and the residue was dissolved in 20% TFA/DCM (2 mL). After 30 mins, the mixture was purified directly by reverse phase HPLC to give compound 19 as a white solid (31 mg). MS: m/z 1309.5 (M+NH4 +).
  • To a stirred solution of compound 19 (25 mg, 20 μmol) in DMF (1 mL) was added acid 20 (16 mg), followed by diisopropylcarbodiimide (8 μL). The mixture was stirred at room temperature for 2 h. The crude reaction mixture was injected to a Prep HPLC column for purification. Compound 21 was obtained a white solid after lyophilization. (12 mg). MS: m/z 1791.4 (M+H+).
    • Example 7 Preparation of Compound 28
  • Figure US20210260211A1-20210826-C00033
    Figure US20210260211A1-20210826-C00034
  • To a stirred solution of compound 2 (50 μmol) in DMSO (1 mL) was added amine 30 (46 mg, 50 μmol) in DMF (1 mL), followed by DIEA (20 μL). The mixture was stirred at room temperature for 16 h. Piperidine (100 μL) was added. After 30 mins, the mixture was purified directly by reverse phase HPLC to give compound 31 in TFA salt form as a white solid (25 mg). MS: m/z 1640.5 (M+H+).
  • Compound 31 (20 mg, 11.4 μmol) was dissolved in DMF (1 mL). Anhydride 13 (8 mg) was added, followed by DIEA (5 μL). The reaction mixture was stirred at room temperature for 5 minutes and purified by reverse phase HPLC to give compound 28 as a white solid after lyophilization (16 mg). MS: m/z 1981.9 (M+H+).
    • Example 8
  • This example provides a comparative study, comparing two different amatinin conjugates shown as “A” and “B” below.
  • Figure US20210260211A1-20210826-C00035
    • Amanitin Antibody Conjugate Structure A (ADC 22)
  • Figure US20210260211A1-20210826-C00036
    • Amanitin Antibody Conjugate Structure B
  • A comparative study was carried out to evaluate the efficacy of amanitin antibody conjugate structure A wherein alpha-amaintin was attached to the linker via a cleavable carbamate bond (reported in this disclosure) and amanitin antibody conjugate structure B wherein alpha amanitin was attached through a non-cleavable ether bond (reported in WO2012/041504) in various in vitro cell killing assays (FIG. 1 four panels for four different cell lines. ADC A completely outperformed ADC B in all 4 Her-2 positive cell lines tested.
    • Example 9
  • This example provides the results of EC50 assays (nM) of the designated drug conjugated antibodies measured in vitro in specified cells. The antibody used was an anti-HER2 IgG class of antibody. Seven breast cancer cell lines with various level of Her2 expression as indicated with plus or minus signs in the table below were plated in 96 well plate. The ADCs were serial diluted and added onto cells for treatment for 5 days. At the end of the study, cell proliferation was measured by Promega's CellTitreGlo. EC50 (in nM) was determined as the concentration of 50% cell growth inhibition. The selection criteria for a successful compound included high efficacy, such as killing cell lines with high expression of the target receptor, with EC50 less than 3 nM. Also, the successful candidate should have low toxicity and good therapeutic window, as determined by relatively low killing of the control cell line (MDA468) with low expression of the target receptor. Both ADCs 22 (FIG. 3) and 24 (FIG. 2) were selected as successful candidates with high efficacy and good therapeutic window.
    • Example 10
  • This example provides the results of EC50 assays (nM) of designated ADCs described herein measured in vitro in specified cells. The antibody used targets a receptor tyrosine kinase on cell surface. Eight cancer cell lines with various level of receptor expression, as indicated with plus or minus signs in the table below, were plated in 96 well plate. The ADCs were serial diluted and added onto cells for treatment for 5 days. At the end of the study, cell proliferation was measured by Promega's CellTitreGlo. EC50 (in nM) was shown below and determined as the concentration of 50% cell growth inhibition. The selection criteria for a successful compound includes high efficacy, such as killing cell lines with high expression of the target receptor, with EC50 less than 3 nM. Also, the successful candidate should have low toxicity and good therapeutic window, as determined by relatively low killing of the control cell lines (T-47D) with low expression of the target receptor. ADC 25 (FIG. 6) shows good cell killing efficacy in cell lines H1993, HCC827, SNU-5, and H292, but did not show efficacy in Hs746T, EBC-1 and U 87. It showed good therapeutic window since it did not kill the negative control cell line T-47 D. ADC 26 (FIG. 4) shows good cell killing activity in H1993 and SNu-5. However, it is not active in the other 6 cell lines. ADC 27 (FIG. 5) shows excellent cell killing activity in H1993 (EC50=11 pM) and SNu-5 (EC50=75 pM). It also shows good efficacy in Hs746T (EC 50=0.4 nM). ADC 29 (FIG. 7) shows good cell killing efficacy in cell lines Hs746T, but did not show efficacy in EBC-1, U87, HCC827, H1993 and T-47.
    • Example 11
  • This example provides the results for the efficacy of ADCs conjugated with small molecule 22, 23, 25, or 27 in a model of H292, HCC827, and H1975 Human Xenograft Tumor Growth in Nude Mice. HCC827, H292, H1975 cell lines were obtained from ATCC. The cells were cultured in RPMI 1640 1× (Corning 10-041-CV) medium with 10% FBS (Seradigm 1500-500) and penicillin streptomycin (Corning 30-002-CI) at 37° C. in a 5% carbon dioxide humidified environment. Cells were cultured for a period of 2 weeks and passaged 4 times before harvest. The cells were harvested with 0.25% trypsin (Corning 25-050-CI). Prior to injection, HCC827 cells were mixed in a 1:1 ratio of HBSS (Hank's balanced salt solution; Ward's 470180-784) and matrigel (Corning 354234) mixture, and 7 million cells per 0.2 ml were injected subcutaneously into the upper right flank of each mouse. H292 cells were resuspended in HBSS, and 5 million cells per 0.2 ml were injected subcutaneously into the upper right flank of each mouse. H1975 cells were resuspended in HBSS, and 3 million cells per 0.2 ml were injected subcutaneously into the upper right flank of each mouse.
  • Female Nu/Nu mice aged 5-7 weeks (Charles River) were used throughout these studies.
  • Upon receipt, mice were housed 5 mice per cage in a room with a controlled environment. Rodent chow and water was provided ad libitum. Mice were acclimated to laboratory conditions for 72 hours before the start of dosing. The animals' health status was monitored during the acclimation period. Each cage was identified by group number and study number, and mice were identified individually by ear tags.
  • The study design and dosing regimens are shown in Table 3.
  • TABLE 3
    Animals Treatment
    Tumor per volume/ Dose/
    model Groups Group route Frequency
    H292
    1 7 PBS 200 μl/i.v. 0 mg/kg,
    single dose
    2 7 cMet/EGFR- 200 μl/i.v. 3 mg/kg,
    22 single dose
    3 7 cMet-22 200 μl/i.v. 3 mg/kg,
    single dose
    4 7 Nimo-22 200 μl/i.v. 3 mg/kg,
    single dose
    HCC827
    1 7 PBS 200 μl/i.v. 0 mg/kg,
    single dose
    2 7 cMet/EGFR- 200 μl/i.v. 3 mg/kg,
    23 single dose
    3 7 cMet-23 200 μl/i.v. 3 mg/kg,
    single dose
    4 7 Nimo-23 200 μl/i.v. 3 mg/kg,
    single dose
    H1975
    1 8 PBS 200 μl/i.v. 0 mg/kg,
    single dose
    2 8 cMet/EGFR- 200 μl/i.v. 1 mg/kg,
    25 single dose
    3 8 cMet/EGFR- 200 μl/i.v. 3 mg/kg,
    25 single dose
    HCC827
    1 8 PBS 200 μl/i.v. 0 mg/kg,
    single dose
    2 8 cMet-27 200 μl/i.v. 0.3 mg/kg,
    single dose
    3 8 cMet/EGFR- 200 μl/i.v. 1 mg/kg,
    27 single dose
    4 8 cMet/EGFR- 200 μl/i.v. 3 mg/kg,
    27 single dose
  • Tumor growth was monitored by measurement of tumor width and length using a digital caliper starting day 5-7 after inoculation, and followed twice per week until tumor volume reached ˜100-250 mm3. Tumor volume was calculated using the formula: Volume (mm3)=[Length (mm)×Width (mm)2]/2. Once tumors were staged to the desired volume, animals were randomized, and mice with very large or small tumors were culled. Mice were divided into groups with animal numbers per group as indicated in study design. Mice were then treated intravenously (0.2 ml/animal) with either PBS or antibody conjugated with 22, 23, 25, or 27 as dose indicated in study design. Tumor growth was monitored, and each group of mice was sacrificed when the average tumor load for the control group exceeded 2000 mm3.
  • Tumor volume was measured twice weekly throughout the experimental period to determine TGI (tumor growth inhibition %). The body weight of each mouse was measured twice weekly by electric balance. Group average and standard deviation were calculated, and statistical analyses (one-way ANOVA with Dunnett's multiple comparison test; GraphPad Prism 6.0) was carried out. All treatment groups were compared with the PBS group. P<0.05 was considered statistically significant.
  • A single dose of cMet/EGFR-22 and Nimo-22 treatment at 3 mg/kg significantly inhibited H292 tumor growth when compared to PBS treated control group. While cMet-22 inhibited tumor growth in the first 10 days after treatment, tumor regained growth after 10 days (FIGS. 8 and 9). In this study, a single dose of cMet/EGFR-22 and cMet-22 at 3 mg/kg showed skin rash at 3-6 days after treatment, and dry, flaky skin between day 6 to 14. Those skin issues recovered after day 14. There was no significant treatment-related body weight loss observed during the study. (FIG. 10). Although there was body weight loss during the first week in cMet/EGFR-22 treated group, the weight loss was transient and less than 10% of total body weight. Also, the animals regained weight and was healthier overall compared to PBS treated control group
  • A single dose of cMet/EGFR-23, cMet-23, or Nimo-23 treatment at 3 mg/kg each significantly inhibited H292 tumor growth when compared to PBS treated control group (FIGS. 11 and 12). No body weight loss was observed in cMet-23, cMet/EGFR-23, and Nimo-23 treated group (3 mg/kg) (FIG. 13).
  • A single dose of cMet/EGFR-25 at 3 mg/kg or 1 mg/kg had no significant tumor growth inhibition in H1975 xenograft (FIG. 14). A single dose of cMet/EGFR-27 at 3 mg/kg or 1 mg/kg, or a single dose of cMet-27 at 0.3 mg/kg had no significant tumor growth inhibition in HCC827 xenograft (FIG. 15). No significant body weight loss was observed during the study (FIG. 16).

Claims (30)

1-3. (canceled)
4. A compound having a structure of the following formula:

L1-L2-X-D
or a pharmaceutically acceptable salt thereof,
wherein:
L1-L2 is a linker selected from
Figure US20210260211A1-20210826-C00037
L2-X has a structure of
Figure US20210260211A1-20210826-C00038
wherein R4 is hydrogen or C1-6 alkyl; and the wavy line indicates the point of attachment to D;
L2 is a linker comprising (a) —R6OC(O)NR5—, and (b) —(CH2)p—, —(CH2CH2O)m—, —C(O)NH—, —NHC(O)—, or a combination of two or more thereof, wherein:
R5 is hydrogen, C1-6 alkyl, —(CH2)p—, —(CH2CH2O)m—, or a combination of two or more thereof;
R6 is Val-Cit-PAB or Ala-Ala-Asn-PAB;
wherein —R6OC(O)NR5— is connected to L1 through R5 or R6;
D is a drug moiety active agent derived from amatoxin having a structure of Formula (II):
Figure US20210260211A1-20210826-C00039
wherein R1 is NH2 or OR2; R2 is H or C1-10 alkyl; R3 is H or OH; and the wavy line indicates the point of attachment to X;
m is an integer from 1-24; and
p is an integer from 1-6.
5. The compound of claim 4, wherein R4 is C1-6 alkyl.
6. The compound of claim 5, wherein R4 is isopropyl.
7. The compound of claim 5, wherein R4 is methyl.
8. The compound of claim 5, wherein L1-L2 is
Figure US20210260211A1-20210826-C00040
9. The compound of claim 5, wherein L2 comprises (a) —R6OC(O)NR5— and (b) —(CH2)p—.
10. The compound of claim 4, wherein R6 is Ala-Ala-Asn-PAB.
11. The compound of claim 4, wherein R6 is Val-Cit-PAB.
12. The compound of claim 4, wherein R5 is —(CH2)p—.
13. The compound of claim 4, wherein R5 is C1-6 alkyl.
14. The compound of claim 13, wherein R5 is methyl.
15. The compound of claim 4, wherein D has a structure of Formula (II):
Figure US20210260211A1-20210826-C00041
wherein R1 is NH2 or OH; R3 is H or OH; and the wavy line indicates the point of attachment to X.
16. The compound of claim 4, which is selected from:
Figure US20210260211A1-20210826-C00042
Figure US20210260211A1-20210826-C00043
17. The compound of claim 16, having the structure:
Figure US20210260211A1-20210826-C00044
18. An antibody drug conjugate (ADC) having the structure of Formula (I):

Ab
Figure US20210260211A1-20210826-Parenopenst
L1-L2-X-D)n   (I)
or a pharmaceutically acceptable salt thereof,
wherein:
Ab is a monoclonal antibody;
L1-L2 is a linker selected from
Figure US20210260211A1-20210826-C00045
wherein the wavy line indicates the point of attachment to Ab;
L2-X has a structure of
Figure US20210260211A1-20210826-C00046
wherein R4 is hydrogen or C1-6 alkyl; and the wavy line indicates the point of attachment to D;
L2 is a linker comprising —R8—S—S—R7—, wherein:
R7 is C2-6 alkylene or —(CH2CH2O)m—;
R8 is selected from C1-6 alkyl, C1-6 alkylene, substituted C1-6 alkylene, —C(O)NH—, —C(O)—NH—CHR9—CR10R11—, —NHC(O)—CHR9—CR10R11—, —(CH2CH2O)m—, and combinations thereof;
R9 is selected from hydrogen, C1-6 alkyl, C1-6 alkylene, —(CH2CH2O)m—, —C(O)NH—, —NHC(O)—, —C(O)NH—(CH2)p—SO3H, C(O)NH—(CH2)p—CO2H, —NHC(O)—(CH2)p—SO3H, —NHC(O)—(CH2)p—CO2H, and combinations thereof;
R10 and R11 are each independently selected from hydrogen, C1-6 alkyl, and combinations thereof;
wherein —R8—S—S—R7— is connected to L1 through R8;
D is a drug moiety active agent derived from amatoxin having a structure of Formula (II):
Figure US20210260211A1-20210826-C00047
wherein R1 is NH2 or OR2; R2 is H or C1-10 alkyl; R3 is H or OH; and the wavy line indicates the point of attachment to X;
n is an integer from 1-10;
m is an integer from 1-24; and
p is an integer from 1-6.
19. The ADC of claim 18, wherein L1-L2 is:
Figure US20210260211A1-20210826-C00048
20. The ADC of claim 18, wherein R4 is C1-6 alkyl.
21. The ADC of claim 20, wherein R4 is methyl.
22. The ADC of claim 18, wherein R7 is C2-6 alkylene.
23. The ADC of claim 18, where Ab is an anti-HER2 antibody.
24. The ADC of claim 18, wherein the ADC is:
Figure US20210260211A1-20210826-C00049
25. A compound having the structure of the following formula:

L1-L2-X-D
or a pharmaceutically acceptable salt thereof,
wherein:
L1-L2 is a linker selected from
Figure US20210260211A1-20210826-C00050
L2-X has a structure of
Figure US20210260211A1-20210826-C00051
wherein R4 is hydrogen or C1-6 alkyl; and the wavy line indicates the point of attachment to D;
L2 is a linker comprising —R8—S—S—R7—, wherein:
R7 is C2-6 alkylene or —(CH2CH2O)m—;
R8 is selected from C1-6 alkyl, C1-6 alkylene, substituted C1-6 alkylene, —C(O)NH—, —C(O)—NH—CHR9—CR10R11—, —NHC(O)—CHR9—CR10R11—, —(CH2CH2O)m—, and combinations thereof;
R9 is selected from hydrogen, C1-6 alkyl, C1-6 alkylene, —(CH2CH2O)m—, —C(O)NH—, —NHC(O)—, —C(O)NH—(CH2)p—SO3H, C(O)NH—(CH2)p—CO2H, —NHC(O)—(CH2)p—SO3H, —NHC(O)—(CH2)p—CO2H, and combinations thereof;
R10 and R11 are each independently selected from hydrogen, C1-6 alkyl, and combinations thereof;
wherein —R8—S—S—R7— is connected to L1 through R8;
D is a drug moiety active agent derived from amatoxin having a structure of Formula (II):
Figure US20210260211A1-20210826-C00052
wherein R1 is NH2 or OR2; R2 is H or C1-10 alkyl; R3 is H or OH; and the wavy line indicates the point of attachment to X;
m is an integer from 1-24; and
p is an integer from 1-6.
26. The compound of claim 25, wherein L1-L2 is:
Figure US20210260211A1-20210826-C00053
27. The compound of claim 25, wherein R4 is C1-6 alkyl.
28. The compound of claim 27, wherein R4 is methyl.
29. The compound of claim 25, wherein R7 is C2-6 alkylene.
30. The compound of claim 25, wherein the compound is:
Figure US20210260211A1-20210826-C00054
31. A method of treating a cancer in an individual in need thereof, comprising administering an effective amount of the ADC of claim 18 to the individual.
32. A method of treating a cancer in an individual in need thereof, comprising administering an effective amount of an antibody drug conjugate (ADC) to the individual, wherein the ADC has the structure of Formula (I):

Ab
Figure US20210260211A1-20210826-Parenopenst
L1-L2-X-D)n   (I)
or a pharmaceutically acceptable salt thereof,
wherein:
Ab is a monoclonal antibody;
L1-L2 is a linker selected from
Figure US20210260211A1-20210826-C00055
wherein the wavy line indicates the point of attachment to Ab;
L2-X has a structure of
Figure US20210260211A1-20210826-C00056
wherein R4 is hydrogen or C1-6 alkyl, and the wavy line indicates the point of attachment to D;
L2 is a linker comprising (a) —R6OC(O)NR5—, and (b) —(CH2)p—, —(CH2CH2O)m—, —C(O)NH—, —NHC(O)—, or a combination of two or more thereof, wherein:
R5 is hydrogen, C1-6 alkyl, —(CH2)p—, —(CH2CH2O)m—, or a combination of two or more thereof;
R6 is Val-Cit-PAB or Ala-Ala-Asn-PAB;
wherein —R6OC(O)NR5— is connected to L1 through R5 or R6;
D is a drug moiety active agent derived from amatoxin having a structure of Formula (II):
Figure US20210260211A1-20210826-C00057
wherein R1 is NH2 or OR2, R2 is H or C1-10 alkyl, and R3 is H or OH; and
the wavy line indicates the point of attachment to X;
n is an integer from 1-10;
m is an integer from 1-24; and
p is an integer from 1-6.
US17/240,700 2016-05-31 2021-04-26 Antibody Drug Conjugates Having Derivatives of Amatoxin As The Drug Pending US20210260211A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/240,700 US20210260211A1 (en) 2016-05-31 2021-04-26 Antibody Drug Conjugates Having Derivatives of Amatoxin As The Drug

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343825P 2016-05-31 2016-05-31
US15/609,858 US11013816B2 (en) 2016-05-31 2017-05-31 Antibody drug conjugates having derivatives of amatoxin as the drug
US17/240,700 US20210260211A1 (en) 2016-05-31 2021-04-26 Antibody Drug Conjugates Having Derivatives of Amatoxin As The Drug

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/609,858 Division US11013816B2 (en) 2016-05-31 2017-05-31 Antibody drug conjugates having derivatives of amatoxin as the drug

Publications (1)

Publication Number Publication Date
US20210260211A1 true US20210260211A1 (en) 2021-08-26

Family

ID=60421192

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/609,858 Active 2037-10-25 US11013816B2 (en) 2016-05-31 2017-05-31 Antibody drug conjugates having derivatives of amatoxin as the drug
US17/240,700 Pending US20210260211A1 (en) 2016-05-31 2021-04-26 Antibody Drug Conjugates Having Derivatives of Amatoxin As The Drug

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/609,858 Active 2037-10-25 US11013816B2 (en) 2016-05-31 2017-05-31 Antibody drug conjugates having derivatives of amatoxin as the drug

Country Status (6)

Country Link
US (2) US11013816B2 (en)
EP (1) EP3471771A4 (en)
JP (2) JP7103953B2 (en)
CN (2) CN115645544A (en)
CA (1) CA3025931A1 (en)
WO (1) WO2017210288A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3025931A1 (en) * 2016-05-31 2017-12-07 Sorrento Therapeutics, Inc. Antibody drug conjugates having derivatives of amatoxin as the drug
WO2017219025A1 (en) 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
WO2018134787A2 (en) 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd137+ cells
JP2021521202A (en) * 2018-04-13 2021-08-26 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング Targeted amatoxin complex for the treatment of solid tumors
AU2019426942B2 (en) * 2019-01-31 2023-11-16 Hangzhou Dac Biotech Co., Ltd A conjugate of an amanita toxin with branched linkers
EP3958908A1 (en) * 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Amatoxin antibody-drug conjugates and uses thereof
WO2020257998A1 (en) * 2019-06-24 2020-12-30 Hangzhou Dac Biotech Co., Ltd A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
US20230241242A1 (en) * 2020-03-25 2023-08-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for antibody medicament conjugate
WO2022184082A1 (en) 2021-03-03 2022-09-09 Sorrento Therapeutics, Inc. Antibody-drug conjugates comprising an anti-bcma antibody
CN113980909B (en) * 2021-11-16 2022-06-14 江南大学 Alpha-amanitin artificial antigen, monoclonal antibody, hybridoma cell strain and application
WO2023173026A1 (en) 2022-03-10 2023-09-14 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041504A1 (en) * 2010-09-30 2012-04-05 Heidelberg Pharma Gmbh Amatoxin-conjugates with improved linkers
WO2013173393A1 (en) * 2012-05-15 2013-11-21 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
US11013816B2 (en) * 2016-05-31 2021-05-25 Sorrento Therapeutics, Inc. Antibody drug conjugates having derivatives of amatoxin as the drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233173B2 (en) 2009-04-08 2016-01-12 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
FR2947320B1 (en) * 2009-06-30 2011-07-22 Valeo Systemes Thermiques CONTROL VALVE FOR A COOLING CIRCUIT OF A MOTOR VEHICLE ENGINE
US20150218220A1 (en) * 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
WO2014193722A1 (en) * 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
WO2015057876A1 (en) * 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
US9239324B2 (en) * 2013-12-06 2016-01-19 Gang Chen Antibody-binding protein-drug conjugate and methods of use
PE20161394A1 (en) * 2013-12-16 2017-01-06 Genentech Inc PEPTIDOMIMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
US20170151339A1 (en) * 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3160513B1 (en) * 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041504A1 (en) * 2010-09-30 2012-04-05 Heidelberg Pharma Gmbh Amatoxin-conjugates with improved linkers
WO2013173393A1 (en) * 2012-05-15 2013-11-21 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
US11013816B2 (en) * 2016-05-31 2021-05-25 Sorrento Therapeutics, Inc. Antibody drug conjugates having derivatives of amatoxin as the drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Burke, et al., Bioconjugate Chem 2009 20:1242 (Year: 2009) *

Also Published As

Publication number Publication date
US11013816B2 (en) 2021-05-25
WO2017210288A1 (en) 2017-12-07
EP3471771A4 (en) 2020-04-15
CN115645544A (en) 2023-01-31
JP2019523761A (en) 2019-08-29
US20170340750A1 (en) 2017-11-30
JP7103953B2 (en) 2022-07-20
EP3471771A1 (en) 2019-04-24
JP7403507B2 (en) 2023-12-22
CN109195631A (en) 2019-01-11
JP2021183646A (en) 2021-12-02
CN109195631B (en) 2022-11-29
CA3025931A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
US20210260211A1 (en) Antibody Drug Conjugates Having Derivatives of Amatoxin As The Drug
AU2020281140B2 (en) Methylene carbamate linkers for use with targeted-drug conjugates
US10590165B2 (en) Antibody drug conjugates
US11970506B2 (en) Bioactive molecule conjugate, preparation method and use thereof
US11510959B2 (en) Hydrophilic antibody-drug conjugates
JP2022043354A (en) Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US20160051695A1 (en) Her2 antibody-drug conjugates
US20170224835A1 (en) Antibody Drug Conjugates
ES2919323T3 (en) Conjugates of quaternized tubulisin compounds
US20210100912A1 (en) Antibody-drug conjugate having acidic self-stabilization junction
CA2338000C (en) Water-soluble 4-thio-maleimido derivatives and methods for their production
US20230277676A1 (en) Camptothecine antibody-drug conjugates and methods of use thereof
US20170281758A1 (en) Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
US6747055B1 (en) Water-soluble drugs and methods for their production
US20220040320A1 (en) Adcs with thiol multiplex linkers
US11091498B2 (en) Topoisomerase poisons
ES2931927T3 (en) Methylene carbamate-based linkers for use with the targeted conjugates

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: JMB CAPITAL PARTNERS LENDING, LLC, CALIFORNIA

Free format text: SECURITY INTEREST;ASSIGNORS:SORRENTO THERAPEUTICS, INC.;SCINTILLA PHARMACEUTICALS, INC.;REEL/FRAME:063283/0063

Effective date: 20230330

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: SCILEX HOLDING COMPANY, CALIFORNIA

Free format text: SECURITY INTEREST;ASSIGNORS:SORRENTO THERAPEUTICS, INC.;SCINTILLA PHARMACEUTICALS, INC.;REEL/FRAME:064441/0575

Effective date: 20230728

AS Assignment

Owner name: SCINTILLA PHARMACEUTICALS, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JMB CAPITAL PARTNERS LENDING, LLC;REEL/FRAME:064571/0848

Effective date: 20230809

Owner name: SORRENTO THERAPEUTICS, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JMB CAPITAL PARTNERS LENDING, LLC;REEL/FRAME:064571/0848

Effective date: 20230809

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

AS Assignment

Owner name: SCINTILLA PHARMACEUTICALS, INC., CALIFORNIA

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNOR:SCILEX HOLDING COMPANY;REEL/FRAME:065017/0844

Effective date: 20230921

Owner name: SORRENTO THERAPEUTICS, INC., CALIFORNIA

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNOR:SCILEX HOLDING COMPANY;REEL/FRAME:065017/0844

Effective date: 20230921

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER